FDA-Aligned Caution (Required Context):FDA safety context (GLP-1 compounding): The FDA has warned about dosing errors associated with compounded injectable semaglutide and noted that some compounders may use salt forms (such as semaglutide sodium or semaglutide acetate)
GLP-1 agonists directly bind these receptors, triggering insulin secretion, slowing gastric emptying, and increasing satiety
Ji L, Jiang H, Cheng Z, Qiu W, Liao L, Zhang Y, et al
Prabhat, P
In the 70s, other appetite suppressants appeared on the scene, recommended for safe (but limited) usage
In contrast to the contrasting views on the impact of GIP on the weight, earlier studies unequivocally demonstrated the weight-reducing effects of GLP-1 and GLP-1RAs in both animals and humans